Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

8 RESEARCH AND DEVELOPMENT Eisai’s R&D mission is to respond to unmet medical needs thus fulfilling customer satisfaction objectives. In achieving this mission, we strive to promote efficient R&D and bring breakthrough prescription drugs to market as quickly as possible. Accordingly, we are concentrating our focus on specific therapeutic areas and are striving to maximize results by capitalizing on advanced technologies in these areas. The success of our drug development efforts owes much to the excellence of our research team leaders and our ability to achieve independent regulatory approval. These team leaders inspire Eisai researchers worldwide to challenge new frontiers in their ongoing drive to develop drugs that contribute to greater customer satisfaction. Concentrated Focus on Strategic Therapeutic Areas Eisai continues to achieve important results by concentrating resources in three strategic therapeutic areas: neurology and gastroenterology— in which we have already established a strong presence—and oncology. The pursuit of focused R&D in these areas enables us to undertake crucial themes and projects at each stage of the drug discovery and development process and concurrently promotes an efficient allocation of resources. This approach also allows us to effectively incorporate cutting-edge information and medical advances at all stages, from exploratory research through clinical research. R&D in the area of central nervous system disorders is based at the Tsukuba Research Laboratories, near Tokyo, and the Eisai London Research Laboratories, in the United Kingdom. The researchers in these facilities cooperate closely. At the same time, both laboratories focus on drug discovery research that capitalizes on its particular strengths. These efforts have contributed to the discovery of such important investigational drugs as E2007, a treatment in for multiple sclerosis. Other substances currently under development include the serotonin receptor antagonist E2101, a centrally acting muscle relaxant, Eisai Annual Report 2001
Selected Research Candidates (As of July 31, 2001) (Phase II and beyond) Research Code Region Stage Description E2020 Japan Approved Alzheimer’s Disease/Acetylcholinesterase Inhibitor Fine Granules (Additional form) U.S. Phase III Dementia with Cerebral Vascular Disease (Additional Indication) U.S. Phase III Severe Alzheimer’s Disease (Additional Indication) U.S. Phase II Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (Additional Indication) Peptic Ulcer/Proton Pump Inhibitor E.U. Approved H. pylori Eradication (Additional Indication) E.U. Approved Symptomatic GERD/Proton Pump Inhibitor (Additional Indication) E3810 U.S. Filed Symptomatic GERD/Proton Pump Inhibitor (Additional Indication) Japan Phase III GERD Maintenance/Proton Pump Inhibitor (Additional Indication) U.S. Phase III H. pylori Eradication (Additional Indication) Muscle Relaxant E2000 Japan Filed Transdermal Patch (Additional Form) E7155 Japan Filed MRI Contrast Medium T-614 Japan Phase III Anti-rheumatic Agent Thrombolytic/Second Generation t-PA E6010 Japan Phase III Pulmonary Embolism (Additional Indication) Japan Phase II Cerebral Embolism (Additional Indication) E3620 Japan Phase II Gastrointestinal Motility 5-HT3 Receptor Antagonist, 5-HT4 Receptor Antagonist KES524 Japan Phase II Obesity Management/Serotonin & Noradrenaline Reuptake Inhibitor E7070 U.S./E.U. Phase II Anti-cancer/Antimitotic Agent E5564 U.S. Phase II Sepsis/Endotoxin Antagonist *Clinical development for new drugs is generally divided into three phases: Phase I : Testing for safety using a small group of healthy subjects. Phase II : Testing for safety and efficacy using a small group of patients. Phase III: Double-blind tests to compare efficacy against similar, existing drugs and other drugs using a large group of patients. and the neurospecific calcium channel blocker E2051, for treating acute cerebral infarction. Our research in this area also includes the clinical development of additional indications for Aricept in the treatment of dementia with cerebral vascular disease, Alzheimer’s disease with severe cognitive impairment, attention deficit disorder and other illnesses. To maximize our ability to respond to unmet medical needs in the area of central nervous system disorders, we have concluded agreements with external firms and individuals. In March 2001, we signed an agreement for the utilization of the genomics database of Incyte Genomics, Inc., a U.S. genomics information company. Also in Eisai Annual Report 2001 9
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9: humanity-based sales activities the
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?